Gary D. Steinberg, MD explains the implications of the BOND-003 results for clinical practice in treating non-muscle-invasive bladder cancer (NMIBC), highlighting the potential benefits of novel immunotherapeutic options like cretostimogene grenadenorepvec as a bladder-sparing therapy for BCG-unresponsive high-risk NMIBC, and discusses how this treatment could fit into the NMIBC treatment landscape if approved.
Video content above is prompted by the following questions:
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.